Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Engineered Peptide Macrocycles Can Inhibit Matrix Metalloproteinases with High Selectivity.

Maola K, Wilbs J, Touati J, Sabisz M, Kong XD, Baumann A, Deyle K, Heinis C.

Angew Chem Int Ed Engl. 2019 Aug 19;58(34):11801-11805. doi: 10.1002/anie.201906791. Epub 2019 Jul 24.

PMID:
31251434
2.

Influence of S-Oxidation on Cytotoxic Activity of Oxathiole-Fused Chalcones.

Konieczny MT, Buɬakowska A, Pirska D, Konieczny W, Skladanowski A, Sabisz M, Wojciechowski M, Lemke K.

Chem Biol Drug Des. 2016 Oct;88(4):519-33. doi: 10.1111/cbdd.12776. Epub 2016 May 20.

PMID:
27198732
3.

Structural factors affecting affinity of cytotoxic oxathiole-fused chalcones toward tubulin.

Konieczny MT, Buɬakowska A, Pirska D, Konieczny W, Skladanowski A, Sabisz M, Wojciechowski M, Lemke K, Pieczykolan A, Strożek W.

Eur J Med Chem. 2015 Jan 7;89:733-42. doi: 10.1016/j.ejmech.2014.10.075. Epub 2014 Oct 30.

PMID:
25462279
4.

Identification of target-binding peptide motifs by high-throughput sequencing of phage-selected peptides.

Rentero Rebollo I, Sabisz M, Baeriswyl V, Heinis C.

Nucleic Acids Res. 2014 Dec 16;42(22):e169. doi: 10.1093/nar/gku940. Epub 2014 Oct 27.

5.

Structural factors affecting cytotoxic activity of (E)-1-(Benzo[d ][1,3]oxathiol-6-yl)-3-phenylprop-2-en-1-one derivatives.

Konieczny MT, Bułakowska A, Polak J, Pirska D, Konieczny W, Gryń P, Skladanowski A, Sabisz M, Lemke K, Pieczykolan A, Gałązka M, Wiciejowska K, Wietrzyk J.

Chem Biol Drug Des. 2014 Jul;84(1):86-91. doi: 10.1111/cbdd.12296. Epub 2014 Feb 28.

PMID:
24476543
6.

Chemical reactivity and antimicrobial activity of N-substituted maleimides.

Salewska N, Boros-Majewska J, Lącka I, Chylińska K, Sabisz M, Milewski S, Milewska MJ.

J Enzyme Inhib Med Chem. 2012 Feb;27(1):117-24. doi: 10.3109/14756366.2011.580455. Epub 2011 May 25.

PMID:
21612375
7.

Synthesis, structure, and tuberculostatic activity of dimethyl benzoylcarbonohydrazonodithioates.

Gobis K, Foks H, Zwolska Z, Augustynowicz-Kopeć E, Główka ML, Olczak A, Sabisz M.

Monatsh Chem. 2011;142(11):1137-1142. Epub 2011 Aug 16.

8.
10.

DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment.

Skladanowski A, Bozko P, Sabisz M.

Chem Rev. 2009 Jul;109(7):2951-73. doi: 10.1021/cr900026u. Review. No abstract available.

PMID:
19522503
11.

Structural determinants of imidazoacridinones facilitating antitumor activity are crucial for substrate recognition by ABCG2.

Bram EE, Adar Y, Mesika N, Sabisz M, Skladanowski A, Assaraf YG.

Mol Pharmacol. 2009 May;75(5):1149-59. doi: 10.1124/mol.109.054791. Epub 2009 Feb 27.

PMID:
19251825
12.
13.

Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy.

Skladanowski A, Bozko P, Sabisz M, Larsen AK.

Cell Cycle. 2007 Sep 15;6(18):2268-75. Epub 2007 Jul 5.

PMID:
17890906
14.

Synthesis of isomeric, oxathiolone fused chalcones, and comparison of their activity toward various microorganisms and human cancer cells line.

Konieczny MT, Konieczny W, Sabisz M, Skladanowski A, Wakieć R, Augustynowicz-Kopeć E, Zwolska Z.

Chem Pharm Bull (Tokyo). 2007 May;55(5):817-20.

15.

Acid-catalyzed synthesis of oxathiolone fused chalcones. Comparison of their activity toward various microorganisms and human cancer cells line.

Konieczny MT, Konieczny W, Sabisz M, Skladanowski A, Wakieć R, Augustynowicz-Kopeć E, Zwolska Z.

Eur J Med Chem. 2007 May;42(5):729-33. Epub 2007 Jan 9.

PMID:
17300856
16.

Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: pharmacologic implications.

Bozko P, Sabisz M, Larsen AK, Skladanowski A.

Mol Cancer Ther. 2005 Dec;4(12):2016-25.

17.

Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.

Skladanowski A, Côme MG, Sabisz M, Escargueil AE, Larsen AK.

Mol Pharmacol. 2005 Sep;68(3):625-34. Epub 2005 Jun 7.

PMID:
15942022

Supplemental Content

Loading ...
Support Center